China SXT Pharmaceuticals (SXTC) Debt to Equity (2018 - 2025)
Historic Debt to Equity for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Q1 2025 value amounting to $0.01.
- China SXT Pharmaceuticals' Debt to Equity fell 8446.76% to $0.01 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.01, marking a year-over-year decrease of 8446.76%. This contributed to the annual value of $0.01 for FY2025, which is 8446.76% down from last year.
- Per China SXT Pharmaceuticals' latest filing, its Debt to Equity stood at $0.01 for Q1 2025, which was down 8446.76% from $0.04 recorded in Q1 2024.
- In the past 5 years, China SXT Pharmaceuticals' Debt to Equity ranged from a high of $0.76 in Q1 2021 and a low of $0.0 during Q1 2022
- In the last 5 years, China SXT Pharmaceuticals' Debt to Equity had a median value of $0.02 in 2023 and averaged $0.17.
- Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 9990.88% in 2022, then soared by 269708.06% in 2023.
- Over the past 5 years, China SXT Pharmaceuticals' Debt to Equity (Quarter) stood at $0.76 in 2021, then plummeted by 99.91% to $0.0 in 2022, then soared by 2697.08% to $0.02 in 2023, then soared by 125.54% to $0.04 in 2024, then plummeted by 84.47% to $0.01 in 2025.
- Its Debt to Equity stands at $0.01 for Q1 2025, versus $0.04 for Q1 2024 and $0.02 for Q1 2023.